Pacific Edge Signs Contract with MediNcrease Health Plan in US
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has entered into an agreement with MediNcrease Health Plans, LLC, a national provider network in the United States, to make Cxbladder available to 5.5 million covered lives through its clients and payers.
This agreement will make Cxbladder tests accessible through MediNcrease’s client base of regional and national health plans, insurance companies, employers, municipalities, third-party administrators, unions and other companies involved in the management of medical claims and will help facilitate expedited payments to Pacific Edge.
Pacific Edge has signed agreements with a number of national and regional provider networks in the US. These networks are an important part of the US healthcare system and help to expedite payment to providers on agreed payment terms.
CEO of Pacific Edge, David Darling, said: “The signing of this agreement reflects the growing acceptance of Cxbladder as an effective, highly accurate and non-invasive test for the detection and better management of urothelial cancer. Having commercial agreements in place with provider networks is an important part of reimbursement of Cxbladder in the US, minimising barriers for urologists who order Cxbladder tests for their patient care.”